Revolax Sub-Q: Regulatory Status and Market Access for Professional Sourcing

Revolax Sub-Q is a hyaluronic acid (HA) dermal filler from South Korean manufacturer Across Biotech. It is formulated for specific aesthetic applications, presenting as a high-viscoelasticity option within the Hyaluronic acid dermal filler catalog. Professionals evaluate such products based on their rheological properties and regulatory clearances, which dictate their suitability for clinical use and market availability.

The initial certification for Revolax Sub-Q originates from its country of manufacture. It holds KFDA approval, a critical benchmark set by the Ministry of Food and Drug Safety in South Korea. For international distribution, particularly within the European Union, a CE Mark is required. Revolax Sub-Q has obtained a CE Mark [VERIFY: Revolax Sub-Q CE Mark status and specific notified body], indicating conformity with EU health, safety, and environmental protection standards.

Regarding other major regulatory bodies:

• FDA Status: Revolax Sub-Q does not currently hold FDA approval for sale within the United States market [VERIFY: Revolax Sub-Q FDA status]. Products without FDA clearance cannot be legally marketed or distributed for aesthetic use in the US.
• GMP/ISO: Across Biotech operates under Good Manufacturing Practice (GMP) standards, and its facilities are typically ISO certified [VERIFY: Across Biotech specific ISO certifications]. These certifications are foundational to product quality and safety, providing assurance for professionals.

The market access of Revolax Sub-Q varies significantly by region, influenced by local regulatory frameworks and product registration processes.

• European Union (EU) and UK: With its CE Mark, Revolax Sub-Q is available for distribution within the EU and, post-Brexit, in the UK, subject to specific national regulations.
• GCC Region: Access in Gulf Cooperation Council (GCC) countries (e.g., UAE, Saudi Arabia) requires specific national registrations often aligned with European standards. Professionals sourcing in this region should verify local import licenses and product registrations.
• LATAM (Latin America): Market entry across Latin American countries is highly fragmented. Each nation, such as Brazil, Mexico, or Argentina, has its own health authority requirements (e.g., ANVISA in Brazil). Availability often depends on specific country-level approvals [VERIFY: Revolax Sub-Q LATAM market registrations].
• APAC (Asia-Pacific): Beyond South Korea, Revolax Sub-Q is widely distributed across various APAC markets, including countries like Thailand, Vietnam, and Malaysia, where specific national regulatory approvals have been secured.

Professionals encounter parallel imports, which are genuine products legally purchased in one country and imported into another without the permission of the original manufacturer. While sometimes offering cost advantages, parallel imports can complicate traceability and guarantee of cold chain integrity. Sourcing from reputable, authorized distributors helps ensure product authenticity and adherence to storage conditions. For similar considerations in market sourcing, professionals can review articles such as Hyaldew Non-Lidocaine: Market Trends and Professional Sourcing.

When sourcing Revolax Sub-Q, professionals must demand specific documentation from their suppliers. This includes:

• Certificate of Authenticity (CoA): Confirms the product is genuine and from the stated manufacturer.
• Batch and Lot Numbers: Allows for complete product traceability from manufacturing to your clinic.
• Cold Chain Documentation: Evidence of maintained temperature controls during transit, crucial for preserving HA filler stability.
• Distributor Authorization: Proof that the supplier is an authorized distributor or has a legitimate supply chain for the product.
• Import/Export Documents: Relevant customs and health authority clearances specific to the destination market.

Ensuring these documents are in order mitigates risks associated with counterfeit products or those compromised by improper handling. This is a standard practice for sourcing all aesthetic products, including other popular options like Elasty Plus 1CC or LEXYAL.

The illustrative wholesale price for Revolax Sub-Q is $95.2/unit, with volume-tiered discounts available: 4% off for 11 units, 5% for 21 units, 6% for 31 units, and 8% for 51+ units. These pricing structures are common in the wholesale market for dermal fillers. Professionals should analyze these tiers to optimize inventory acquisition costs, similar to the strategies discussed in our Monalisa Volume Wholesale Price Guide for Professional Sourc. Strategic inventory management ensures both cost-effectiveness and consistent product availability for clinic operations.